Inivata Ltd (Inivata), a subsidiary of NeoGenomics Inc., is a cancer genomics company that harnesses liquid biopsy platforms to enhance personalized healthcare in oncology. The company’s product portfolio includes InVisionFirst – Lung, which offers advanced sequencing technology to detect copy number variants, single nucleotide variants, insertions and deletions, and structural variants in selected genes from DNA isolated from plasma samples from patients with non-small cell lung cancer; and InVisionSeq test. Inivata collaborates with industry and academic researchers to develop new clinical applications for liquid biopsy and ctDNA analysis. The company operates across the UK and the US. Inivata is headquartered in Cambridge, Cambridgeshire, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Inivata Ltd
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Inivata Ltd Company Overview
Inivata Ltd Company Snapshot
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview
Inivata Ltd – Pipeline Analysis Overview
Inivata Ltd - Key Facts
Inivata Ltd - Major Products and Services
Inivata Ltd Pipeline Products by Development Stage
Inivata Ltd Ongoing Clinical Trials by Trial Status
Dec 27, 2023: Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
Dec 05, 2023: NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Jul 27, 2023: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Jun 15, 2023: Neogenomics’ RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Jun 05, 2023: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
May 30, 2023: NeoGenomics to showcase the transformational impact of RaDaR assay for molecular residual disease and recurrence monitoring at ASCO
Apr 06, 2023: NeoGenomics to share nine abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
Mar 16, 2023: NeoGenomics announces commercial availability of the RaDaR Molecular Residual Disease Test
Feb 06, 2023: RaDaR(R) assay demonstrates clinical potential for helping Oncologists determine whether or not muscle-invasive bladder cancer patients undergo radical surgery
Nov 21, 2022: RaDaR(R) Assay demonstrates clinical potential for detecting disease recurrence across all types of early breast cancer, including triple negative disease
Table 22: RaDaR Assay - Liquid Biopsy for Minimal Residual Disease Detection in Head and Necksquamous Cell Carcinoma (LIONESS) Study
Table 23: RaDaR Assay - SURVIVE (Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer) - a Partially Double-blinded, Multi-center, Randomized, Controlled Superiority Study
Table 24: Inivata Ltd, Key Employees
Table 25: Glossary
List of Figures
Figure 1: Inivata Ltd Pipeline Products by Equipment Type
Figure 2: Inivata Ltd Pipeline Products by Development Stage
Figure 3: Inivata Ltd Ongoing Clinical Trials by Trial Status